The use of Non-Steroids Antiinflammatory and Antirheumatic Medicines in the UK has shown a general decline over the past decade. From 2013 to 2023, the Defined Daily Dosage (DDD) per thousand persons per day decreased from 28.6 to 20.5 units, equivalent to a compound annual growth rate (CAGR) of -2.02%. The most significant yearly decline was observed in 2017, with a year-on-year reduction of 7.69%, while 2021 experienced a reversal with a slight increase of 3.85%. The trend continued downward with -2.78% in 2022 and -2.38% in 2023.
The forecasted data from 2024 to 2028 predicts a continued decline, albeit at a slower pace, with a forecasted 5-year CAGR of -2.21%. The anticipated DDD will drop further to 17.8 by 2028, reflecting an overall reduction of 10.55% over the forecast period.
Future trends to watch for in the use of Non-Steroids Antiinflammatory and Antirheumatic Medicines include:
- Innovation in alternative treatments reducing reliance on non-steroidal options.
- Impact of emerging health policies and guidelines on prescription practices.
- Public health initiatives focusing on preventive measures for arthritis and inflammatory conditions.
- Potential socioeconomic factors influencing accessibility and affordability of medicines.
